A case study on ketamine reveals systemic barriers that prevent repurposing existing low-cost drugs like ketamine for treatment-resistant depression.
  • seaQueue@lemmy.world
    4·
    1 year ago

    I mean, just with basic knowledge of healthcare and pharmaceuticals in the US you can deduce that low cost treatments like ketamine aren’t available because they can’t produce the same level of profit as a freshly patented new drug. US wealthcare isn’t interested in low cost treatments that work quickly with a minimum number of interventions, the entire system is setup to keep patients on maintenance doses of maximally profitable drugs as long as possible.